Clinical Trial Update: Itacitinib for Low Risk GVHD [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for itacitinib in low-risk acute GVHD has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Itacitinib (itacitinib)

Snippet

Sponsor: John Levine | Conditions: Low Risk Acute Graft-versus-host Disease, Graft-versus-host-disease | Phase 2 | Status: COMPLETED | Results posted: 2023-02-06